(Q24246376)

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: A randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

A controlled trial of hypotensive agents in hypertension in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Fetal outcome in trial of antihypertensive treatment in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

First year of life after the use of atenolol in pregnancy associated hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Atenolol in essential hypertension during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Effect of antihypertensive drugs on neonatal blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Glycemia in newborns of hypertensive mothers according to maternal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Short-term metabolic effects of isradipine and metoprolol in pre-eclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Flow velocity analysis of umbilical and uterine artery flow in pre‐eclampsia treated with propranolol or pindolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Effects of acute L-arginine infusion on non-stress test in hypertensive pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Effect of calcium channel blocker nifedipine on uterine artery flow velocity waveforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Randomized controlled study comparing effect of magnesium sulfate with placebo on fetal umbilical artery and middle cerebral artery blood flow in mild preeclampsia at ≥ 34 weeks gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

The detection, investigation and management of hypertension in pregnancy: full consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Diuretics for preventing pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

The classification and definition of the hypertensive disorders of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Reduced salt intake compared to normal dietary salt, or high intake, in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Drugs for treatment of very high blood pressure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Abdominal decompression for suspected fetal compromise/pre-eclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Antiplatelet agents for preventing and treating pre-eclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Oral beta-blockers for mild to moderate hypertension during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Effects of nifedipine on resistance vessels, arteries and veins in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Measuring diastolic blood pressure in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Pre-eclampsia: more than pregnancy-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Studies on hydralazine; evidence for a peripheral site of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

Nifedipine administered in pregnancy: effect on the development of children at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

The measuring of blood pressure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Effect of methyldopa and isradipine on fetal heart rate pattern assessed by computerized cardiotocography in human pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Management of pregnancy-induced hypertension with pindolol--comparative study with methyldopa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Management of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Hypertension during pregnancy, with and without specific hypotensive treatment. I. Perinatal factors and neonatal morbidity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

OS013. Reduction of preeclampsia related complications with with theNO-donor penterythriltetranitrat (petn) in risk pregnancies - Aprospective randomized double-blind placebo pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The role of nitric oxide in the pathogenesis of preeclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Revised definition of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The effect of nitric oxide on uterine and umbilical artery flow velocity waveform in pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The effect of nifedipine on urinary excretion of calcium in preeclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Effect ofl-arginine on blood pressure in pregnancy-induced hypertension: A randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Use of labetalol and methyldopa in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Preeclampsia: haemostatic status and the short-term effects of methyldopa and isradipine therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Neonatal head circumference and the treatment of maternal hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Hypertension during pregnancy with and without specific treatment; the development of the children at the age of four years.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Blood rheology in pre-eclampsia and intrauterine growth retardation: effects of blood pressure reduction with labetalol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Gruppo di Studio Ipertensione in Gravidanza

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Evaluation of a definition of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Lack of consistency in research papers over the definition of pre-eclampsia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Atenolol in essential hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Comparison of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Intrauterine exposure to the beta-adrenergic receptor-blocking agent metoprolol and allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Neonatal adaptation in hypertensive pregnancy--a study of labetalol vs hydralazine treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Randomised controlled trial of methyldopa and isradipine in preeclampsia--effects on uteroplacental and fetal hemodynamics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension A randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

24-Hour Ambulatory Blood Pressure Monitoring: A Comparison Between Transdermal Glyceryl-Trinitrate and Oral Nifedipine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021

Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002252.PUB2

7 January 2021